Abstract
Depression is a common co-morbidity in patients with cardiovascular diseases such as chronic coronary artery disease, acute coronary syndromes, post by-pass surgery and chronic heart failure. There is a significant body of evidence suggesting that the presence of depression is independently associated with a decline in health status and an increase in the risk of hospitalization and death for patients with coronary artery disease or congestive heart failure. Novel treatment modalities such as selective serotonin re-uptake inhibitors (SSRIs) may improve depressive symptoms and prognosis of post-myocardial infarction and heart failure patients interacting with the common pathophysiologic mechanisms of depression and cardiovascular disease. This review summarizes current experimental and clinical evidence regarding the pleiotropic effects of SSRIs on platelet functions, immune and neurohormonal activation, and cardiac rhythm disturbances in patients with cardiovascular disease. These bio-modulatory properties of SSRIs may be translated into improvement of patient clinical outcomes beyond their anti-depressant action.
Keywords: SSRIs, depression, cardiovascular disease, platelets, cytokines
Cardiovascular & Hematological Agents in Medicinal Chemistry
Title: Selective Serotonin Re-Uptake Inhibitors for the Treatment of Depression in Coronary Artery Disease and Chronic Heart Failure: Evidence for Pleiotropic Effects
Volume: 4 Issue: 4
Author(s): Ioannis Paraskevaidis, John T. Parissis, Katerina Fountoulaki, Gerasimos Filippatos and Dimitrios Kremastinos
Affiliation:
Keywords: SSRIs, depression, cardiovascular disease, platelets, cytokines
Abstract: Depression is a common co-morbidity in patients with cardiovascular diseases such as chronic coronary artery disease, acute coronary syndromes, post by-pass surgery and chronic heart failure. There is a significant body of evidence suggesting that the presence of depression is independently associated with a decline in health status and an increase in the risk of hospitalization and death for patients with coronary artery disease or congestive heart failure. Novel treatment modalities such as selective serotonin re-uptake inhibitors (SSRIs) may improve depressive symptoms and prognosis of post-myocardial infarction and heart failure patients interacting with the common pathophysiologic mechanisms of depression and cardiovascular disease. This review summarizes current experimental and clinical evidence regarding the pleiotropic effects of SSRIs on platelet functions, immune and neurohormonal activation, and cardiac rhythm disturbances in patients with cardiovascular disease. These bio-modulatory properties of SSRIs may be translated into improvement of patient clinical outcomes beyond their anti-depressant action.
Export Options
About this article
Cite this article as:
Paraskevaidis Ioannis, Parissis T. John, Fountoulaki Katerina, Filippatos Gerasimos and Kremastinos Dimitrios, Selective Serotonin Re-Uptake Inhibitors for the Treatment of Depression in Coronary Artery Disease and Chronic Heart Failure: Evidence for Pleiotropic Effects, Cardiovascular & Hematological Agents in Medicinal Chemistry 2006; 4 (4) . https://dx.doi.org/10.2174/187152506784111454
DOI https://dx.doi.org/10.2174/187152506784111454 |
Print ISSN 1871-5257 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6182 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Role of Oxidative Stress and Anti-Oxidant Treatment in Platinum- Induced Peripheral Neurotoxicity
Current Cancer Drug Targets Current Pharmacological Approach to Restore Endothelial Dysfunction
Cardiovascular & Hematological Agents in Medicinal Chemistry Protein Aggregation and Self Assembly in Health and Disease
Current Proteomics Epigenetics in Neurodegenerative Diseases: The Role of Histone Deacetylases
CNS & Neurological Disorders - Drug Targets Calcium Channel Mutations in Cardiac Arrhythmia Syndromes
Current Molecular Pharmacology Advantages and Limitations of Current Biomarker Research: From Experimental Research to Clinical Application
Current Pharmaceutical Biotechnology Review of the Relationship between Renal and Retinal Microangiopathy in Diabetes Mellitus Patients
Current Diabetes Reviews Vitamin D Receptor Agonists: Opportunities and Challenges in Drug Discovery
Current Topics in Medicinal Chemistry Tyrosine Kinase Inhibitors – A Review on Pharmacology, Metabolism and Side Effects
Current Drug Metabolism Xanthine Oxidase and its Role as Target in Cardiovascular Disease: Cardiovascular Protection by Enzyme Inhibition?
Current Pharmaceutical Design The Inflammatory Response in Cardiac Surgery: An Overview of the Pathophysiology and Clinical Implications
Inflammation & Allergy - Drug Targets (Discontinued) Metabolism and Pharmacological Mechanisms of Active Ingredients in <i>Erigeron breviscapus</i>
Current Drug Metabolism Turnover Studies on Cardiac Natriuretic Peptides: Methodological,Pathophysiological and Therapeutical Considerations.
Current Drug Metabolism Etiologic Aspects of Pagets Disease of Bone
Current Rheumatology Reviews Glycerophospholipid Synthesis as a Novel Drug Target Against Cancer
Current Molecular Pharmacology Apoptosis in the Homeostasis of the Immune System and in Human Immune Mediated Diseases
Current Pharmaceutical Design Arrhythmia Pharmacogenomics: Methodological Considerations
Current Pharmaceutical Design The Pleiotropic Effects of Inducible Nitric Oxide Synthase (iNOS) on the Physiology and Pathology of Penile Erection
Current Pharmaceutical Design Coated with Nanomaterials Intraocular Lenses, Ophthalmic and Human Body Implantable Devices with High Catalytic Antioxidant Activities: A New Nanotechnology Strategy of Peroxidase Cellular Enzyme Mimics Increasing the Biocompatibility and Therapeutic Deployment of the Medical Prosthetic Device
Recent Patents on Drug Delivery & Formulation Selective Pharmacological Inhibition of the Pacemaker Channel Isoforms (HCN1-4) as New Possible Therapeutical Targets
Current Medicinal Chemistry